Deep Dive on Market Access

Deep Dive

Views & Analysis

Breaking policy and perceptual barriers: Biosimilars

Experts from Research Partnership analyse the company’s Therapy Watch data to identify how market access policy has impacted the adoption of biosimilars.

Views & Analysis

Digital health and pharma – adapting to the post-coronavirus...

The need for digital transformation and a response model for coronavirus were among the topics discussed in a recent digital debate

Views & Analysis

Deep Dive: Market Access - Breaking Barriers

In this issue of Deep Dive we look at the changing landscape for pharma market access and start to assess the impact of the COVID-19 pandemic.

Views & Analysis

6 ways to digitise your business at pace

As the COVID-19 pandemic stretches on, can your business survive without face-to-face customer contact?

Digital

Time to fix pharma’s outdated business model

The disconnect between payers and pharma companies is just one symptom of pharma’s outdated business model, according to Janssen’s company group chairman EMEA, Kris Sterkens.

Digital

Bringing gene therapies to market

Doug Danison, vice-president, head of access, value and evidence strategy at bluebird bio, a gene therapy company, looks at the obstacles, opportunities and required change in thinking need

Breaking policy and perceptual barriers: Biosimilars

Digital health and pharma – adapting to the post-coronavirus...

Deep Dive: Market Access - Breaking Barriers

6 ways to digitise your business at pace

Time to fix pharma’s outdated business model

Bringing gene therapies to market

Allergy Tx plots grass pollen jab launch after German okay

The AI imperative: Establishing the standard for modern clin...

Deep Dive

Editor's Picks